European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-30

Dreaming of no more renal dialysis: how self-derived tissue and cells can replace renal function

Cel

For chronic kidney diseases there is little chance that the vast majority of the world¿s population will have access to renal replacement therapy with dialysis. There is yet no adequate alternative with curative intent than allo-transplantation. This approach is seriously impaired by eventually limited graft survival and by the scarce availability of donors. We propose an innovative strategy that would help to simultaneously overwhelm the reduced access to dialysis, the need for organs for transplantation, the avoidance of patient exposure to immunosuppressants. The overall focus is based on the idea of generating new kidneys by tissue engineering technologies starting from a whole-kidney scaffold with intact three-dimensional geometry and vasculature created by de-cellularization of a kidney harvested from the patient with progressive chronic kidney disease (CKD). Repopulation of the kidney scaffold could be achieved with patient-specific induced pluripotent stem (iPS) cells generated by reprogramming to a pluripotent status of somatic cells. After regeneration, the kidney will be transplanted in the same patient. Thereafter, the same procedures will be repeated with the contralateral native injured kidney, after in vivo assessment of the proper functional performance of the newly generated transplanted organ.
This goal will be pursued through the three steps introductory to the development of the best strategy for translating the proposed frontier research to patients with CKD:
1.Create an intact whole-kidney scaffold by de-cellularization of a rodent kidney and validate the
procedure with a human kidney.
2. Attempt to reconstruct the organ by reseeding the rodent and human whole-kidney scaffolds
with iPS cells generated by reprogramming adult dermal fibroblasts to a pluripotent status.
3. Deeply characterize the function of the new rodent and human kidneys by in vivo and in vitro
techniques.

Zaproszenie do składania wniosków

ERC-2010-AdG_20100317
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

ERC-AG - ERC Advanced Grant

Instytucja przyjmująca

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Wkład UE
€ 2 493 000,00
Adres
VIA MARIO NEGRI 2
20156 Milano
Włochy

Zobacz na mapie

Region
Nord-Ovest Lombardia Milano
Rodzaj działalności
Research Organisations
Kontakt administracyjny
Maria Grazia Pezzoni (Ms.)
Kierownik naukowy
Giuseppe Remuzzi (Prof.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)